SCHEMBL4303219

SCHEMBL4303219

O=C(O)CN1C(=O)c2cccc(NC(=O)c3ccc(Cl)s3)c2C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.46
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
STK33 Q9BYT3 1/20 0.44
KMT2A Q03164 4/20 0.43
KDM4E B2RXH2 4/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 2/20 0.43
CYP1A2 P05177 1/20 0.43
AKR1B1 P15121 1/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
F10 P00742 1/20 0.43
RPS6KA2 Q15349 2/20 0.42
ACHE P22303 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4314316 0.89 ACHE (0.45) HPGDALDH1A1SMN1; SMN2STK33KMT2A
SCHEMBL13950025 0.85 ALDH1A1 (0.47) HPGDALDH1A1SMN1; SMN2STK33KMT2A
SCHEMBL5781838 0.84 HDAC1 (0.47) HPGDALDH1A1SMN1; SMN2CA12STK33
SCHEMBL3377540 0.84 HDAC1 (0.45) HPGDALDH1A1SMN1; SMN2CA12STK33
SCHEMBL4308690 0.83 STK33 (0.40) HPGDALDH1A1SMN1; SMN2STK33KMT2A
SCHEMBL13950089 0.83 ALDH1A1 (0.46) HPGDALDH1A1SMN1; SMN2STK33KMT2A
SCHEMBL4309863 0.83 GAA (0.45) HPGDALDH1A1SMN1; SMN2STK33KMT2A
SCHEMBL4305643 0.82 HPGD (0.42) HPGDALDH1A1SMN1; SMN2STK33KMT2A
SCHEMBL4306024 0.82 GAA (0.44) HPGDALDH1A1SMN1; SMN2STK33KMT2A
SCHEMBL13950054 0.82 F10 (0.54) HPGDALDH1A1SMN1; SMN2STK33KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482472-B2 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2009-01-27 US disclosed
US-7482472-B2 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2009-01-27 US disclosed
US-7482472-B2 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2009-01-27 US disclosed
US-20080039446-A1 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2008-02-14 US disclosed
US-20080039446-A1 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2008-02-14 US disclosed
US-20080039446-A1 Substituted isoindoles and their use BAYER HEALTHCARE AG (DE) 2008-02-14 US disclosed
US-7189738-B2 Substituted isoindoles and their use thereof BAYER HEALTHCARE AG (DE) 2007-03-13 US disclosed
US-7189738-B2 Substituted isoindoles and their use thereof BAYER HEALTHCARE AG (DE) 2007-03-13 US disclosed
US-7189738-B2 Substituted isoindoles and their use thereof BAYER HEALTHCARE AG (DE) 2007-03-13 US disclosed
EP-1414817-B1 substituted isoindoles and the use thereof BAYER HEALTHCARE AG (DE) 2005-04-06 EP disclosed
US-20040215019-A1 Substituted isoindoles and the e use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039446-A1 Substituted isoindoles and their use F2, F12, TFPI2 HPGD 195/4885ALDH1A1 346/4885SMN1; SMN2 1980/4885
US-20040215019-A1 Substituted isoindoles and the e use thereof F2, F12, F5 HPGD 433/4885ALDH1A1 166/4885SMN1; SMN2 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.